Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 12/20 | 0.60 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | HINT1 | P49773 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1582054 | 1.00 | TYMP (0.60) | TYMPTAS1R3TAS1R1KDM4ENT5E | |
| SCHEMBL30679321 | 0.97 | TYMP (0.57) | TYMPTAS1R3TAS1R1KDM4ENT5E | |
| SCHEMBL7764877 | 0.95 | TYMP (0.60) | TYMPTAS1R3TAS1R1KDM4ENT5E | |
| SCHEMBL21878043 | 0.95 | TYMP (0.60) | TYMPTAS1R3TAS1R1KDM4ENT5E | |
| SCHEMBL31390209 | 0.94 | TYMP (0.56) | TYMPTAS1R3TAS1R1KDM4ENT5E | |
| SCHEMBL21160996 | 0.94 | TYMP (0.68) | TYMPTAS1R3TAS1R1HINT1ADORA1 | |
| SCHEMBL21160998 | 0.94 | TYMP (0.68) | TYMPTAS1R3TAS1R1HINT1ADORA1 | |
| SCHEMBL18954966 | 0.94 | TYMP (0.68) | TYMPTAS1R3TAS1R1HINT1ADORA1 | |
| SCHEMBL18954969 | 0.94 | TYMP (0.68) | TYMPTAS1R3TAS1R1HINT1ADORA1 | |
| SCHEMBL19493329 | 0.94 | TYMP (0.68) | TYMPTAS1R3TAS1R1HINT1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170296655-A1 | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-19 | — | — | US | disclosed |
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2008100447-A2 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | SLC29A1, NUDT1, EIF2AK2 | TYMP 40/4885TAS1R3 4231/4885TAS1R1 3479/4885 |
| US-20170296655-A1 | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway | CGAS, PDE11A, MAVS | TYMP 688/4885TAS1R3 3270/4885TAS1R1 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.